Recruiting
Phase 1

Photodynamic Nails

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06083896

Conditions

Pelvic Metastasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Photodynamic nails

Study Details

Brief summary:

Determine whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure

Conditions

Pelvic Metastasis

Study ID

NCT06083896

Start date

Oct 6, 2023

Status verified date

Aug, 2026

Completion date

Jan 1, 2029

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must have a histologically confirmed malignancy from prior biopsy of the primary tumor or a metastatic site. Patients with carcinoma, myeloma, and lymphoma may be included in the study. Patients should have metastatic involvement of the periacetabular region that is visible radiographically. Biopsy of acetabular disease is not required for this study.
  • Age ≥18 years (Illuminoss is approved only for skeletally mature patients)
  • Suitable candidate for general anesthesia
  • Ability to understand and the willingness to sign a written informed consent document.
  • Able and willing to fill out pre-operative and post-operative functional outcome surveys
  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelets ≥ 50,000/mcL

Exclusion Criteria:

  • Patients with uncontrolled intercurrent illness (e.g., recent pneumonia or myocardial infarction that would significantly increase risk of general anesthesia)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because of the risk of general anesthesia and radiation exposure (fluoroscopy) to the fetus
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to dental resins or PET.

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Interventions

Photodynamic nails

stab incision is made at the entry site

Primary outcome measure

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: Through study completion, up to one year ]

Central Contacts and Locations

Central contacts

Patrick Lin, MD

(713) 745-0088plin@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Patrick Lin, MD

713-745-0088plin@mdanderson.org

Principal Investigator:

Patrick Lin, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-12.